{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=30", "query": { "intervention": "Phase 1b", "page": 30 }, "page_size": 10 }, "pagination": { "page": 30, "page_size": 10, "total_count": 2481, "total_pages": 249, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=31&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=29&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T19:52:19.337Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02913313", "title": "A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Broad Solid Tumor" ], "interventions": [ { "name": "BMS-986207", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2016-11-30", "completion_date": "2024-01-25", "has_results": true, "last_update_posted_date": "2025-04-20", "last_synced_at": "2026-10-20T19:52:19.337Z", "location_count": 6, "location_summary": "Hackensack, New Jersey • New York, New York • Philadelphia, Pennsylvania + 2 more", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02913313" }, { "nct_id": "NCT00646906", "title": "Mechanisms of Action of Acetaminophen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Myocardial Infarction", "Arthritis" ], "interventions": [ { "name": "Aspirin First", "type": "DRUG" }, { "name": "Aspirin Last", "type": "DRUG" }, { "name": "Acetaminophen 1000 mg/d", "type": "DRUG" }, { "name": "Acetaminophen 4000 mg/d", "type": "DRUG" }, { "name": "Ibuprofen 800 mg/d", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 55, "start_date": "2004-06-02", "completion_date": "2012-01-24", "has_results": true, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-10-20T19:52:19.337Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00646906" }, { "nct_id": "NCT04207255", "title": "Addition of Opaganib to Androgen Antagonists in Patients With mCRPC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Opaganib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 69, "start_date": "2020-03-27", "completion_date": "2024-07-31", "has_results": true, "last_update_posted_date": "2024-09-25", "last_synced_at": "2026-10-20T19:52:19.337Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Charleston, South Carolina", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04207255" }, { "nct_id": "NCT04809467", "title": "A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "tafasitamab", "type": "DRUG" }, { "name": "parsaclisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2021-09-16", "completion_date": "2024-10-22", "has_results": true, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-10-20T19:52:19.337Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04809467" }, { "nct_id": "NCT01987232", "title": "Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Extensive-Stage Small-Cell Lung Cancer" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2013-11-05", "completion_date": "2017-05-04", "has_results": true, "last_update_posted_date": "2017-08-28", "last_synced_at": "2026-10-20T19:52:19.337Z", "location_count": 11, "location_summary": "New Haven, Connecticut • Gainesville, Florida • Goshen, Indiana + 8 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Muncie", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01987232" }, { "nct_id": "NCT05626322", "title": "Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Maplirpacept", "type": "DRUG" }, { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-08-04", "completion_date": "2025-05-01", "has_results": true, "last_update_posted_date": "2025-09-05", "last_synced_at": "2026-10-20T19:52:19.337Z", "location_count": 4, "location_summary": "Baton Rouge, Louisiana • Ann Arbor, Michigan • Providence, Rhode Island", "locations": [ { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT05626322" }, { "nct_id": "NCT02576899", "title": "Improving Functional Outcomes of Veterans With PTSD and Tobacco Dependence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tobacco", "Posttraumatic Stress Disorder" ], "interventions": [ { "name": "Acceptance and Commitment Therapy for PTSD and Tobacco Use", "type": "BEHAVIORAL" }, { "name": "Freedom From Smoking", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2015-09-01", "completion_date": "2019-12-31", "has_results": true, "last_update_posted_date": "2020-04-10", "last_synced_at": "2026-10-20T19:52:19.337Z", "location_count": 1, "location_summary": "Bedford, Massachusetts", "locations": [ { "city": "Bedford", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02576899" }, { "nct_id": "NCT03565406", "title": "A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Mocetinostat Induction Phase + Ipilimumab + Nivolumab", "type": "DRUG" }, { "name": "Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 11, "start_date": "2018-04-25", "completion_date": "2020-01-13", "has_results": false, "last_update_posted_date": "2020-05-21", "last_synced_at": "2026-10-20T19:52:19.337Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03565406" }, { "nct_id": "NCT03145298", "title": "ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pulmonary Arterial Hypertension (PAH)" ], "interventions": [ { "name": "Allogeneic Human Cardiosphere-Derived Stem Cells", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 26, "start_date": "2017-10-01", "completion_date": "2023-03-31", "has_results": false, "last_update_posted_date": "2023-06-12", "last_synced_at": "2026-10-20T19:52:19.337Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03145298" }, { "nct_id": "NCT05413421", "title": "Study of ORIC-944 in Patients With Metastatic Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Prostate Cancer" ], "interventions": [ { "name": "ORIC-944", "type": "DRUG" }, { "name": "Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets", "type": "DRUG" }, { "name": "Apalutamide (Erleada™) 60 mg or 240 mg tablets", "type": "DRUG" }, { "name": "Darolutamide (Nubeqa®) 300 mg tablets", "type": "DRUG" }, { "name": "Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ORIC Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 275, "start_date": "2022-06-01", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-20T19:52:19.337Z", "location_count": 20, "location_summary": "Colorado Springs, Colorado • Plantation, Florida • Arlington Heights, Illinois + 17 more", "locations": [ { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Plantation", "state": "Florida" }, { "city": "Arlington Heights", "state": "Illinois" }, { "city": "Lake Barrington", "state": "Illinois" }, { "city": "Jeffersonville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05413421" } ] }